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SOMMARIO 
OBIETTIVI. Studiare l’effetto della Pilocarpina sulla composizione proteica salivare in soggetti 
affetti da sindrome di Sjögren primitiva (pSS) e comparare il profilo proteico dei soggetti affetti da 
pSS con soggetti sani di controllo e pazienti affetti da sindrome di Sjögren secondaria (sSS). E’ 
stata inoltre ricercata la presenza di immunopeptidi, come le defensine e le timosine, allo scopo di 
descriverne l’eventuale presenza e l’abbondanza relativa nella saliva di soggetti affetti da SS e di 
valutarne il possibile ruolo come biomarker di malattia e/o di infiammazione.     
METODI. Sono  stati analizzati campioni di saliva di 9 pazienti affetti da pSS, 9 sSS e 10 soggetti 
sani mediante High Performance Liquid Chromatography e Mass Spectrometer-Electrospray 
Ionization Source. In 6 pazienti con pSS sono stati raccolti campioni di saliva anche dopo 30, 60 
minuti e 24 ore dall’assunzione di 5 mg di Pilocarpina.  
RISULTATI. Nei campioni basali, più del 50% delle proteine salivari di origine ghiandolare 
analizzate risultavano non rilevabili all’indagine spettrometrica o mostravano livelli 
significativamente più bassi nei pazienti con pSS rispetto ai soggetti sani. I pazienti con sSS 
mostravano un profilo di proteine salivari intermedio tra i pazienti con pSS ed i soggetti di 
controllo. Circa un terzo delle proteine meno rappresentate nei pazienti con pSS al basale 
risultavano rilevabili con frequenza simile ai controlli dopo 60 minuti dall’assunzione di 
Pilocarpina. Tutte le proteine con livelli significativamente più bassi al basale rispetto ai controlli 
raggiungevano livelli simili ai soggetti sani dopo 30 minuti dall’assunzione di Pilocarpina. La 
migliore risposta al farmaco è stata osservata tra le proteine di origine parotidea. I pazienti con pSS 
erano inoltre caratterizzati da alti livelli di -defensina 1 e dalla presenza di -defensina 2, peptidi di 
origine neutrofilica ed epiteliale rispettivamente, con funzioni antimicrobiche. Mentre la -timosina 
4, peptide strutturale con proprietà antinfiammatorie e riparatrici, risultava rilevabile in quasi tutti i 
soggetti sani e nei pazienti, la -timosina 10, è stata riscontrata nella maggior parte dei pazienti con 
pSS e in un terzo dei soggetti con sSS; non era invece evidenziabile in nessuno dei soggetti sani.  
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CONCLUSIONI. Il nostro studio ha dimostrato come la Pilocarpina, farmaco secretagogo agonista 
colinergico, che si riteneva aumentare solo la quota fluida della secrezione salivare, sia invece in 
grado di ripristinare parzialmente i livelli ed il numero delle proteine salivari ridotte in corso di 
sindrome di Sjögren. L’ -defensina 1, la -defensina 2 e la -timosina 10 potrebbero essere 
considerati biomarker di infiammazione orale nei pazienti con pSS.  
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INTRODUCTION 
SJGREN’S SYNDROME AND PILOCARPINE TREATMENT 
Saliva is a complex fluid composed of a variety of electrolytes, metabolites, nucleotides, 
polynucleotides and proteins; it plays an important role in the maintenance of oral health (1). The 
rate of salivary protein secretion is controlled mainly by noradrenalin that is released from the 
sympathetic terminals and acts through the -adrenergic receptors, while the rate of fluid and 
electrolyte secretion is controlled by acetylcholine, released from the parasympathetic terminals and 
acting through the muscarinic cholinergic receptors (2). A large number of systemic agents has been 
proposed as secretagogues, but only a few have shown consistent salivary secretion enhancing 
properties in well-designed trials. Among cholinergic agonists, pilocarpine is the most effective for 
protein secretion in rat (3), having also a mild -adrenergic stimulating properties, but a few data 
have been reported in humans. Pilocarpine has been shown to improve symptoms of oral dryness 
and to increase salivary output in patients with primary Sjögren’s syndrome (pSS) (4), a chronic 
autoimmune disorder of the exocrine glands with associated lymphocytic infiltrates and consequent 
dryness of mouth and eyes (5). Saliva composition in pSS patients has been found to be different 
from normal subjects (6). However the pattern of salivary gland proteins in patients with pSS is not 
completely defined with regard to its composition, mainly in relation to low-molecular-weight 
components as acidic and basic proline-rich proteins (PRPs), statherins and cystatins, as well as 
defensins, which are immunopeptides of epithelial and neutrophilic origin, and thymosins, G-actin-
sequestering peptides with immuno-regulatory properties. In particular there are no data concerning 
the effects of pilocarpine on salivary protein profile in pSS patients. Moreover there are no studies 
on the possible differences in salivary protein profile between pSS and Sjögren’s syndrome 
associated to other rheumatic diseases (sSS). 
 
 5 
SALIVARY PEPTIDES 
The table 1 shows the main salivary proteins classes and their origin. 
 
Table 1. Main salivary proteins classes and their origin. 
Salivary gland proteins Parotid glands Submandibular/sublingual 
glands 
Lysozyme + + 
Salivary Cystatins - + 
Statherin + + 
Histatins + + 
Acidic PRPs + + 
Basic PRPs  + - 
 
 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
The pattern of salivary gland proteins in health and disease is not completely defined with regard to 
its composition, mainly in relation to these low-molecular-weight components. 
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Prolyn rich proteins (PRPs) are the main components in human saliva (table 2 and 3).  They are 
classified in basic, acidic and glycosilated. Since their role is not well understood it seems that these 
proteins are involved in the metabolism of calcium in the mouth (7’).   
Table 2: acidic PRPs (Swiss Prot code P02810) found through HPLC-ESI MS. 
 
 
Protein 
 
Mean theoric 
mass 
[M]  
 
 
Mean 
experimental 
mass [M]  
 
 
PRP-2 (PRP-1,  PIF-s)                                           di-P. 
 
15514 (15515)  
 
15515 ±2 
 
PRP-2 (PPR-1, PIF-s)                                           tri- P.  
 
15594 (15595) 
 
15595 ±2 
 
PRP-2 (PPR-1, PIF-s)                                     mono- P. 
 
15434 (15435) 
 
15434 ±2 
 
Db-s                                                                       di- P. 
 
17633 
 
17633 ±3 
 
Db-s                                                                      tri- P. 
 
17713 
 
17713 ±3 
 
Db-s                                                                 mono- P. 
 
17553 
 
17553 ±2 
 
Pa monomer                                                        di- P. 
 
15462 
 
15462 ±2 
 
Pa dimer                                                          tetra- P. 
 
30922 
 
30922 ±3 
 
Pa dimer                                                              tri- P. 
 
30842 
 
30842 ±3 
 
Pa dimer                                                               di- P. 
 
30762 
 
30762 ±3 
 
Pa dimer des Gln 150                                     tetra- P. 
 
30794 
 
30793 ±2 
 
PRP-4 ( PRP-3, PIF-f)                                          di- P. 
 
11161 (11162 ) 
 
11162 ±2 
 
PRP-4 (PRP-3,  PIF-f)                                    mono- P. 
 
11081 (11082) 
 
11081 ±3 
 
PRP-4 ( PRP-3, PIF-f)                                       non- P. 
 
11001 (11002) 
 
11002 ±1 
 
PRP-4 ( PRP-3, PIF-f) des Arg 106                     di- P. 
 
11005 (11006) 
 
11006 ±1 
 
Db-f                                                                      di- P. 
 
13280 
 
13280 ±2 
 
Db-f                                                                mono- P 
 
13200 
 
13200 ±2 
 
PC peptide  
 
4371 
 
4371 ±1 
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Table 3: basic PRPs found through RP-HPLC-ESI MS 
 
 
   
Peptide 
 
 
 Swiss-Prot 
code 
 
Mean theoric 
mass 
[M] 
Mean 
experimental 
mass  [M] 
                             P-C  (IB-8b) 
 
P02810 4371  4371 
P-F (IB-8c) P02812 5843 (0) 5843 
P-J (IB-6 fr. 1-62) P04280 5945 (1) 5944 
P-E (IB-9) P02811 6024 (0) 6024 
P-D (IB-5) P02813 6950 (1) 6950 
P-H (IB-4) (IB-6 fr. 63-118) P04280 5590 (0) 5590 
IB-8a  - 11894 (1) 11898 
IB-6 P04280 11517 (2) 11519 
IB-1 P04281 9593 (0) 9593 
II-2 - 7609 (1) 7608 
IB-1 non-P P04281 9513 (1) 9512 
II-2 non-P - 7529 (1) 7528 
IB-1 des Arg 96 P04281 9437 (0) 9437 
II-2 des Arg 75 - 7453 (1) 7452 
P-B P02814 5793 (1) 5793 
Fragm P-B (fr.8-57) P02814 5215 (1) 5215 
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Cystatins are composed by 115-120 amino acid, with molecular weight of 13-14 kDa and 2 
sulphidrilic bridges. They have inhibitor activity against cystein (8’). Group S only has a 
glandular origin (table 4).  
 
Table4: Cystatins found through HPLC-ESI MS. 
 
 
Protein 
 
Swiss-Prot 
code 
 
Mean theoric mass 
[M] 
 
Mean experimental 
mass [M] 
 
Cystatin S 
 
P01036 
 
14188.7 
 
14187 
Cystatin S1 “ 14268.7 14267 
Cystatin S2 “ 14348.7 14348 
Cystatin SN P01037 14316.0 14315 
Cystatin SA P09228 14350.0 14345 
Cystatin C P01034 13347.1 13345 
Cystatin D P28325 13858.6 13848 
Cystatin A P01040 11006.5 11006 
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DEFENSINS 
Defensins are a family of small cationic proteins, 3000-4000 Da, involved not only in the innate 
immune system against infectious microbes, but also in adaptive immunity (9-11), inflammation 
and wound repair (12). The human defensin family is subdivided into  and -defensins on the basis 
of the spatial distribution of the cysteine residues and connectivity of disulfide-bonds (13). -
defensins 1-4 were isolated from neutrophil cells and 5-6 are present in secretory granules of the 
intestinal Paneth’s cells and in epithelial cells of the female genital tract (14). -defensins 1-3 
constitute the most abundant proteins of azurophil granules composing 30-50 % of the protein 
content (15).  -defensin-4 is two orders of magnitude less abundant than 1-3 (16). -defensins 1-3 
genes are constitutively expressed in neutrophils and there is no evidence that factors other than 
gene copy number influence the expression of -defensins 1-3 (17). The expression of -defensins 
in cells other than neutrophils has been reported in buccal epithelial cells of subjects with oral 
pathology (18) and in the striated duct cells of the submandibular glands (19). High performance 
liquid chromatography and mass spectrometry have shown the presence of -defensins 1-3 in 
normal subjects saliva (20), moreover our group has recently found the presence of low levels of -
defensin-4 in gingival crevicolar fluid (GCF) of normal subjects (21) (table 5).GCF is one of the 
main sources of oral -defensins. In normal subjects GCF concentration of -defensins is 
approximately from five to fifteen times greater than that one determined in whole saliva.  
Human -defensins 1-4 have been described in some detail, but many additional human - 
defensins genes exist and their functions remain to be explored (22). -defensins 1-4 are expressed 
by many epithelial cells, especially in oral tissues (23,24). Oral keratinocytes but not fibroblasts 
express -defensins 1-2 (25), moreover -defensins-1 and 2 have also been detected in salivary 
glands and ducts (26,27). -defensin-1 is constitutively and heterogeneously expressed in epithelial 
cells and only poorly induced by cytokines (28), while -defensins-2 and 3 expression can be 
induced by a local cytokine imbalance with a predominance of Th1 cytokines as TNF, IL 1 and 
IL 6 for -defensin-2 and INF for -defensin-3 as in oral inflammatory diseases or by infectious 
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agents by LPS (29). However significant individual heterogeneity in -defensin gene expression has 
been reported (30, 31) as result of genetic polymorphisms or number of defensin gene copies (32), 
multiple regulatory pathways and mediators involved in their expression (33), different grade of 
tissue atrophy (34) or the replacing of the innate or natural defence by mechanisms of the acquired 
immune response in chronically inflamed tissues (35). In fact some studies have suggested 
increased expression of -defensins-2 and 3 in tissues with inflammation (36, 37), whereas other 
investigators have shown decreased  expression in inflamed oral tissue samples (38). Kawasaki S et 
al reported a significantly up-regulation of -defensin-2 gene but not of other -defensins genes in 
conjunctival epithelial cells from pSS patients (39). 
 
Table 5:  -defensins found trough RP-HPLC-ESI-MS 
peptide Mean theoric mass [M]   Mean experimental mass [M] 
-Defensin 2 
-Defensin 1 
-Defensin 3 
3371.0      (P59665/P59666) 
3442.1       (P59665) 
3486.1       (P59666) 
3371.8 
3442.6 
3486.9 
-Defensin 4 3709.4        (P12838) 3709.5 
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THYMOSINS 
β-thymosins are a family of peptides with a molecular mass of about 5 kDa and with a sequence of 
40-44 amino acid residues. All β-thymosins, so far isolated, are acetylated at the N terminus; they 
are soluble and stable in diluted acid and are cpmosed by almost all polar amino acids. The name 
thymosin derives from the first isolation of these peptides from calf thymus, while the , β and γ 
letters divide thymosins according to their different isoelectric points (below 5.0, between 5.0 and 
7.0, above 7.0, respectively) (40). So far, more than 15 -thymosins have been described and many 
more have been detected in cDNA library (40). In mammalian tissues thymosin β4 (Tβ4) is usually 
the main peptide, representing about 70-80% of the total -thymosin content. 
Tβ4 is an ubiquitous peptide with very interesting functions. Initially Tβ4 was embraced as a G-actin 
sequestring peptide, but biochemical and overexpression studies showed that Tβ4 exerts its 
intracellular action not only as a monomer-buffering protein but also indirectly via activation and 
transcription of signalling molecules that alter the actin cytoskeleton. Thus, manipulation of the 
actin cytoskeleton can induce transcriptional, translational, and post-translational changes in crucial 
proteins within the actin regulatory network (41).  
Some of its functions require full-length Tβ4 or Tβ4 fragments containing the actin-binding motif (N 
terminus), while others appear to be mediated  through the N-terminal AcSDKP peptide that does 
not bind actin (41). Tβ4 promotes cell migration and adhesion dynamics directly modulating actin 
polymerization/ depolymerization but also forming a functional complex with PINCH and ILK, 
from integrin network, that activates the prosurvival kinase Akt (42). Tβ4 treatment or 
overexpression decreases the amount of E-cadherin, which stabilizes cell-cell adhesion and inhibits 
motility, mechanism involved in malignant transformation and differentiation (43). 
Tβ4’s properties to adopt a secondary structure after interaction with other proteins may allow it to 
bind multiple unrelated partners. This would explain why how such a small peptide can have such a 
wide spectrum of biological effects in vivo (44). Moreover tandem beta-thymosin motif containing 
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proteins can bind actin filament promoting actin assembly rather than preventing actin 
polymerization (45). TB4 itself acts as a monomer-sequestering protein at low concentrations and 
binds actin filaments at high concentrations (46). However, when TB4 increases acutely, it tends to 
depolymerize actin filaments,  this suggests that TB4 act primarily as an actin-sequestering protein 
shifting the monomer:polymer equilibrium toward depolymerization (47). 
Recently it has also become clear that Tβ4 has an important extracellular role in the repair and 
remodelling of tissues and organ systems. Tβ4 plays a role in regulation and differentiation of T 
lymphocytes (48) and can inhibit the migration of macrophages (49). Moreover, Tβ4 exerts 
biological effects on hypothalamus and pituitary gland (50). Tβ4 induces matrix metalloproteinases, 
modifies the rate of spreading of endothelial cells on matrix components (51,52), stimulates the 
migration of human umbilical vein endothelial cells (53), it is involved in the repair of damaged 
cornea (54,55), induces hair growth by activating hair follicle stem cells (56), it might be involved 
in the development and repair of damages of the heart and brain (57,58). The molecular mechanism 
underlying these effects are until now unknown, as well as the mechanism of release from cells. 
When Tβ4 is released in the extracellular space by blood platelets it can be cross-linked by factor 
XIIIa either to fibrin or fibrinogen, preferentially to the αC-domain, by other tissue 
transglutaminases to collagen and actin (59). This provides a mechanism to increase the local 
concentration of Tβ4 at sites of clot formation and tissue damage, where it may contribute to wound 
healing, angiogenesis, and inflammatory responses.  
Tβ4 sulfoxide is the product of oxidation of the methionyl residue at position 6. This oxidation 
increases the dissociation constant about 20-fold. Because cells produce peroxides (e.g. H2O2) 
during their metabolism, it has been hypothesized that this mechanism could regulate Tβ4 actin-
binding activity lowering its affinity to G-actin (40). Moreover Tβ4 sulfoxide seems to have anti-
inflammatory properties and can inhibit neutrophil chemotaxis (60). In lymphoid tissue Tβ4 gene 
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also encodes a longer splice variant carrying an additional 98-pair exon at 5’, which was found to be 
expressed in murin skin T / cells and showed anti-inflammatory activities (61).  
Tβ4 and Tβ10 bind actin with similar affinity (62) but Tβ10 is less abundant in normal tissue. 
However Tβ10 is greater expressed in preneoplastic and neoplastic tissues (63) and in activated 
lymphocytes (64). Tβ4 has been recently detected in human whole saliva and tears (65), while Tβ4 
sulfoxide and Tβ10 have never been described in human saliva.  
Our group found that Tβ4 is almost always detectable in whole saliva, while its sulfoxide was 
sporadically and Tβ10 was rarely detectable. The relative abundance of Tβ4 in salivary secretions 
from parotid and submandibular/sublingual gland is often undetectable, when compared to the 
abundances observed in whole saliva. Analysis of crevicular gengival fluid reveals high relative 
abundances of Tβ4, its sulfoxide and Tβ10, being all them always detectable. Tβ4 is always the 
most abundant in crevicular fluid. These results indicate that gengival plexus is a relevant source for 
oral Tβ4 and Tβ10 (66). 
Tβ4 has been detected in human whole saliva and tears by immunological technique (65). 
Commercial available immunological tests cross-react with sulphoxide thymosins, while RP-HPLC 
allow to distinguish nonoxided and oxided thymosins, because the oxidation of a methionyl residue 
decreases the elution time. Moreover splice-variant can also be detected by RP-HPLC. There are no 
study reporting the presence of Tβ4, Tβ4 sulfoxide or thymosin β10 (Tβ10) in saliva of patients with 
Sjögren’s syndrome.  
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OBJECTIVES 
The aims of this work have been to investigate the effect of pilocarpine on salivary peptide and 
protein profile in pSS patients, in order to analyze the differences between patients before and after 
pilocarpine assumption and healthy controls. Moreover the salivary profile in patients with pSS  
was also investigated. 
The presence and levels of defensins and thymosins were also investigated in order to characterize 
their possible role as biomarker of disease or inflammation.     
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PATIENTS AND METHODS 
Patients were enrolled at the Rheumatology Clinic, Catholic University, Rome. After obtaining the 
informed consent, saliva specimens were collected from: 
9 pSS patients (all females, mean age 55.8 ± 13, mean duration of disease 7.9 ± 4.2), 
9 sSS patients (3 with Systemic Sclerosis (SSc), 3 with Systemic Lupus Erythematous (SLE) and 3 
with Rheumatoid Arthritis (RA); all females, mean age 48.5 ± 16.4, mean duration of disease 5.7 ± 
5.1) 
10 healthy subjects who did not show any sign of Sjögren’s syndrome (SS) symptoms and were 
negative for immunologic and serologic tests and matched for sex and age. 
Saliva specimens were also collected in 6 pSS patients after 30, 60 minutes and 24 hours from 5 mg 
pilocarpine intake. All patients were diagnosed according to the revised international classification 
criteria for SS (67). Whole saliva was collected using a very soft plastic aspirator between 2 and 4 
pm in order to reduce concentration variability connected to circadian rhythms of secretion. The 
collection was performed at least 30 min after any food or beverage admission and tooth brushing. 
An acidic solution (0.2% TFA) was immediately added in ice bath to all collected salivary samples 
in 1:1 v/v ratio and the solution centrifuged at 8000 g at 4° C for 5 min. After discharge of 
precipitate the acidic solution was analysed by High Performance Liquid Chromatography coupled 
with Mass Spectrometer equipped with Electrospray Ionization Source (HPLC-ESI-MS) within 30 
min from collection.  
The HPLC-ESI-MS apparatus was a ThermoFinnigan (San Jose, CA, USA) Surveyor HPLC 
connected by a T splitter to a PDA diode-array detector and to a Xcalibur LCQ Deca XP Plus mass 
spectrometer. The mass spectrometer was equipped with an electrospray ion (ESI) source. The 
chromatographic column was a Vydac (Hesperia, CA, USA) C8 column, with 5 µm particle diameter 
(column dimensions 150x2.1 mm). The following solutions were utilized for the reversed-phase 
chromatography: (eluent A) 0.056% (v/v) aqueous TFA and (eluent B) 0.050% (v/v) TFA in 
acetonitrile-water 80/20 (v/v). The gradient applied was linear from 0 to 55% of B in 40 min, at a 
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flow rate of 0.30 mL/min. The T splitter addressed a flow-rate of about 0.20 mL/min towards the 
diode array detector and a flow-rate of about 0.10 mL/min towards the ESI source. The diode array 
detector was set at the two wavelengths of 214 and 276 nm. Mass spectra were collected every 3 
millisecond in the positive ion mode. MS spray voltage was 4.50 kV and the capillary temperature 
was 220° C. All common chemicals and reagents for the HPLC-MS analysis were of analytical grade 
and were purchased from Farmitalia-Carlo Erba, (Milan, Italy), Merck (Damstadt, Germany) and 
Sigma Aldrich (St. Louis, MI, USA).  
 
DATA ANALYSIS  
Deconvolution of average ESI mass spectra was automatically performed either by the software 
provided with the Deca-XP instrument (Bioworks Browser) or by MagTran 1.0 software (Zhang and 
Marshall, 1998). Experimental mass values obtained from the analysis were compared with average 
theroretical values available from the Swiss Prot and EMBL data banks 
(http://www.expasy.org/tools; http://www.embl-heidelberg.de).  
The relative amount of the different salivary proteins was approximately computed by performing a 
multiple eXtracted Ion Current (XIC) strategy for any protein. The XIC procedure for a protein was 
based on the extraction from the Total Ion Current (TIC) profile to three m/z values selected among 
the most relevant, provided that these did not overlap with m/z values of nearly eluting proteins. For 
the peptides with a mass comprised in the detection range of the ESI-MS apparatus (300-2000), the 
mono-isotopic m/z values of either the mono-charged or of the bi-charged ion or both was chosen for 
the XIC procedure. Taking into account that constant analytical conditions were used for each 
sample, the numerical value corresponding to the integrated peak area of the XIC strategy was used 
for the statistical analysis and for rough estimation of relative changes in protein amount between 
two states.  
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Experimental Mass values were compared with average theoretical values available at the Swiss-
Prot data bank (http://us.expasy.org/tools), where -defensins 1-3 can be found with the codes 
P59665-P59666 and -defensin 4 with the code P12838. Average mass values of -defensins are 
the following: -defensin 1, 3442.1; -defensin 2, 3371.0; -defensin 3, 3486.1; -defensin 4, 
3709.4 Da. Relative abundances of -defensins were evaluated by considering the area of the XIC 
peaks, revealed in the total chromatographic TIC by selecting the following double-, triple- and 
tetra-charged ions: -defensin 1, 1722.1, 1148.4, 861.5 (± 0.5); -defensin 2, 1686.5, 1124.7, 843.8 
(± 0.5); -defensin 3, 1744.1, 1163.0, 872.5 (± 0.5);  -defensin 4, 1855.7, 1237.5, 928.4 (± 0.5). 
The area of the XIC peaks under similar experimental conditions is linearly related to the peptide 
concentration, as verified using standards of defensin 1 and 2. Elution time of -defensins 1-3 was 
coincident at 23.7 (± 0.7) min, while -defensin 4 eluted as a separate peak at 27.4 (± 0.7) min. 
 
Experimental Mass values were compared with average theoretical values available at the Swiss-
Prot data bank, where Tβ4 and Tβ10 have the P62328 and P63313 codes, respectively. Relative 
abundances of β thymosins were evaluated by considering the area of the XIC peaks, revealed in 
the total chromatographic TIC by selecting the following charged ions: Tβ4, [M+5H]5+ = 993.8 m/z 
; [M+4H]4+ = 1241.9 m/z ; [M+3H]3+ = 1655.5 m/z (Maverage: 4963.5). Tβ10, [M+5H]5+ = 988.3 m/z ; 
[M+4H]4+ = 1235.1 m/z ; [M+3H]3+ = 1646.5 m/z (Maverage: 4936.5).   
 
Data statistical treatment was carried out by SPSS 13.0 (SPSS. Chicago. IL-USA). Categorical and 
quantitative variables were respectively described as numbers, percentage (%) and mean ± standard 
deviation (SD). Mann-Whitney’s test and Wilcoxon’s test were used to compare continuous 
variable. Categorical variables were analysed using χ2 test or Fisher’s test, depending on sample 
size restrictions. 
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RESULTS 
Analysis of frequency and levels of salivary gland proteins in pSS patients vs healthy controls  
The principal salivary gland protein classes and their origin are listed in table 1. In the 9 pSS 
patients, 28 (43.8%) of the 64 proteins analyzed were significantly less detectable than in the 10 
healthy controls (Tables 6-11). Especially salivary cystatins were less frequently found in pSS 
patients; only the cystatin A was found in a similar percentage in patients and in controls according 
to its not glandular origin. Only one peptide had a detection frequency higher in pSS patients than in 
controls: the PB Des1-4 peptide was found in 6/9 (60 %) of patients with pSS vs 1/10 (10 %) of 
controls (p=0.017).  
Among proteins whose detection frequency was similar between pSS patients and controls, 8 
(12.5%: IB-1, II-2 PRP-1, PRP-3, statherin, PC, P-B peptide) were less abundant in pSS patients 
than in controls (Tables 6-11).   
Then 27 (56.3%) of the proteins analyzed were not detectable or showed lower levels in pSS 
patients than in controls. 
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Table 6. Basic PRPs levels/frequency in controls, sSS and pSS before and after pilocarpine 
 
 
Controls(10)  sSS(9)   pSS(9) T0 pSS(6) T30’  pSS(6) T60’ pSS(6) T24 h 
Basic PRPs       
P-F 16±27 (10//10) 3.7±6.3 (5/9) 2.4±3.7 (4/9*) 8.4±7.0 (4/6°) 5.0±3.5 (5/6°) 4.4±3.6 (5/6°) 
P-J 13±20 (10/10) 4.9±8.2 (5/9) 2.9±4.2 (5/9) 11±7.4† (5/6) 6.7±7.5† (5/6) 4.9±3.5 (5/6) 
P-E nv (1/10) 1.6±3.4 (4/9) nv (1/9) 5.8±9.0 (2/6) nv (1/6) nv (1/6) 
P-D 9.5±16 (8/10) 13±20 (8/9) 9.2±13 (8/9) 27±21† (6/6) 25±29† (6/6) 13±9.5 (6/6) 
P-H 17±25 (10/10) 5.6±7.8 (7/9) 4.7±5.6 (7/9) 14±11 (5/6) 11±11† (6/6) 7.6±5.7 (5/6) 
IB-8a 12±19 (6/10) nv (0/9*) nv (0/9*) nv (0/6) nv (0/6) nv (0/6) 
IB-6 nv (1/10)  4.3±6.6 (5/9*) nv (0/9) 3.8±5.8 (2/6) nv (1/6) nv (1/6) 
IB-1 29±41 (10/10) 11±17* (8/9) 3.3±5.3* (6/9) 14±14‡ (6/6) 12±13 (6/6) 6.9±5.5 (5/6) 
II-2 67±13 (10/10) 14±22 (7/9) 5.8±9.2* (7/9) 33±28‡ (6/6) 26±19 (6/6) 14±8.3 (6/6) 
IB-1 DesR 1.6±2.8 (7/10) nv (1/9*) 0.9±2.5 (2/9*) 2.1±4.7 (2/6) 2.3±4.9 (2/6) 0.1±2.7 (1/6) 
II-2 DesR 2.8±4.1 (10/10) 3.5±4.9 (5/9) 3.9±4.1 (7/9) 2.3±5.9 (5/6) 3.2±6.3 (5/6) 3.1±3.9 (5/6) 
IB-7 0.07±0.1 (2/10) nv (0/9) nv (0/9) nv (0/6) nv (0/6) nv (0/6) 
Levels expressed in Extracted Ion Current area  x 10^8 and detection frequency in brackets; pSS: primary Sjögren’s syndrome patients; sSS: 
secondary Sjögren’s syndrome patients; nv: not valuable;  *p<0.05 versus controls; °detection frequency significantly increased; †p<0.05 versus T0;  
‡ p<0.05 versus T0 and p>0.05 versus controls 
 
 
 
 
Table 7. Acidic PRPs proteins levels/frequency in controls, sSS and pSS before and after pilocarpine 
 
 
Controls(10)  sSS(9)   pSS(9) T0 pSS(6) T30’  pSS(6) T60’ pSS(6) T24 h 
Acidic PRPs       
PRP-1 3P 1.0±1.3 (10/10) 3.0±7.5 (5/9) 0.2±0.5 (3/9*) 0.4±0.6 (3/6) 0.3±0.4 (2/6) 0.4±0.5 (3/6) 
PRP-1  29±26 (10/10) 11±16 (7/9) 1.7±2.3* (6/9) 3.5±2.3‡ (5/6) 4.8±2.8† (6/6) 3.0±3.5 (6/6) 
PRP-1 1P 2.9±2.1 (9/10) 2.8±6.6 (7/9) 0.3±0.4 (3/9*) 0.8±0.8 (5/6°) 0.9±0.5 (6/6°) 0.5±0.7 (5/6°) 
PRP-3  17±18 (10/10) 15±16 (9/9) 1.5±2.1* (6/9) 4.6±3.6† (5/6) 5.9±5.0‡ (6/6) 3.2±3.1† (5/6) 
PRP-3 1P 1.8±1.3 (10/10) 1.4±1.5 (8/9) 0.3±0.4 (4/9*) 0.6±0.5 (5/6°) 5.9±12 (6/6°) 0.5±0.5 (4/6°) 
PRP-3 0P 0.06±0.08 (5/10) 0.9±1.5 (5/9) 0.4±0.8 (3/9) 0.7±0.9 (3/6) 0.8±0.6† (5/6) 0.5±0.7 (3/6) 
PC 32±29 (10/10) 13±17 (7/9) 7.8±9.5* (9/9) 26±19‡ (6/6) 29±22‡ (6/6) 15±10 (6/6) 
PC desQ 0.4±0.4 (9/10) 0.2±0.3 (4/9*) 0.4±0.5 (5/9) 0.8±1.1 (4/6) 1.0±1.4 (4/6) 0.3±0.4 (3/6) 
PC desPQ 0.8±0.9 (9/10) nv (1/9*) 0.5±1.1 (2/9*) 0.6±1.0 (3/6°) nv (1/6) 0.5±0.8 (2/6) 
Levels expressed in Extracted Ion Current area  x 10^8 and detection frequency in brackets; pSS: primary Sjögren’s syndrome patients; sSS: 
secondary Sjögren’s syndrome patients; nv: not valuable;  *p<0.05 versus controls; °detection frequency significantly increased; †p<0.05 versus T0;  
‡ p<0.05 versus T0 and p>0.05 versus controls 
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Table 8. Sthaterin levels/frequency in controls, sSS and pSS before and after pilocarpine 
 
 
Controls(10)  sSS(9)   pSS(9) T0 pSS(6) T30’  pSS(6) T60’ pSS(6) T24 h 
Statherin        
Stath 45±26 (10/10) 16±23* (8/9) 5.8±13* (7/9) 12±13 (5/6) 13±16‡ (5/6) 12±22 (5/6) 
Stath 1P 0.9±0.7 (10/10) 0.3±0.5 (3/9*) 0.4±0.5 (5/9) 0.3±0.2 (4/6) 0.2±0.3 (3/6) 0.2±0.3 (2/6) 
Stath 0P 0.03±0.06 (3/10) 0.3±0.4 (5/9) 0.3±0.3 (5/9) 0.09±0.1 (3/6) nv (1/6) nv (1/6) 
SV1 2.3±2.3 (10/10) 2.8±3.4 (8/9) 1.5±2.2 (7/9) 2.3±3.0 (6/6) 1.7±1.3 (6/6) 2.9±4.8 (6/6) 
Stath DesTF 1.2±1.3 (10/10) 0.8±1.1 (7/9) 0.6±0.8 (6/9) 0.5±0.7 (3/6) 2.6±3.5 (4/6) 0.7±0.8 (4/6) 
Stath DesD1 0.9±0.8 (10/10) 0.3±0.4 (6/9) 0.8±0.2 (4/9*) 0.3±0.3 (3/6) 0.5±0.7 (3/6) 0.5±0.7 (3/6) 
SV2 0.4±0.3 (9/10) 0.09±0.2 (2/9*) nv (0/9*) nv (0/6) nv (0/6) nv (0/6) 
SV3 nv (1/10) nv (0/9) nv (0/9) nv (0/6) nv (0/6) nv (0/6) 
Stath Des1-9 1.4±1.0 (10/10) 0.9±1.5 (5/9) 0.2±0.4 (3/9*) 0.6±0.8 (3/6) 0.4±0.3 (4/6°) 0.5±0.7 (3/6) 
Stath Des1-10 0.4±0.3 (10/10) 0.6±0.7 (6/9) 0.3±0.7 (3/9*) 0.6±0.8 (3/6) 0.6±0.8 (4/6°) 0.6±0.8 (3/6) 
Stath Des1-13 0.3±0.2 (10/10) 0.4±0.4 (6/9) 0.3±0.4 (5/9)  0.3±0.4 (3/6) 0.5±0.5 (4/6°) 0.3±0.4 (3/6) 
P-B peptide 24±15 (10/10) 18±20 (8/9) 8.9±11* (9/9) 14±12‡ (6/6) 9.6±20 (6/6) 12±16 (6/6) 
P-B Des1-5 0.8±0.9 (9/10) 1.2±1.8 (7/9) 2.4±3.1 (7/9) 1.4±1.8 (5/6) 3.2±4.5 (5/6) 1.9±3.4 (4/6) 
P-B Des1-4 nv (1/10)  0.6±1.1 (3/9*) 0.9±1.1 (6/9*) 0.8±0.8 (5/6) 1.1±1.7 (4/6) 0.8±1.2 (4/6) 
P-B Des1-7 2.1±1.4 (9/10) 3.7±3.9 (8/9) 1.6±2.3 (7/9) 3.5±2.8 (6/6) 5.1±4.1 (6/6) 3.5±3.3 (5/6) 
Levels expressed in Extracted Ion Current area  x 10^8 and detection frequency in brackets; pSS: primary Sjögren’s syndrome patients; sSS: 
secondary Sjögren’s syndrome patients; nv: not valuable;  *p<0.05 versus controls; °detection frequency significantly increased; †p<0.05 versus T0;  
‡ p<0.05 versus T0 and p>0.05 versus controls 
 
 
 
 
Table 9. Cystatins levels/frequency in controls, sSS and pSS before and after pilocarpine 
 
 
Controls(10)  sSS(9)   pSS(9) T0 pSS(6) T30’  pSS(6) T60’ pSS(6) T24 h 
Cystatins       
Cyst A 1.0±1.2 (10/10) 1.7±1.8 (9/9) 5.0±7.3*(8/9) 2.3±2.9 (5/6) 1.7±1.8 (4/6) 2.0±2.4 (4/6) 
Cyst C 0.7±0.4 (9/10) nv (0/9*) nv (0/9*) nv (0/6) nv (0/6) nv (0/6) 
Cyst D nv (0/10) nv (0/9) nv (0/9) nv (0/6) nv (0/6) nv (0/6) 
Cyst S 0.5±0.4 (10/10)  nv (0/9*) nv (0/9*) nv (0/6) nv (0/6) nv (0/6) 
Cyst S1 5.9±4.6 (10/10)  3.9±6.1 (5/9) 1.9±3.2 (4/9*) 3.4±5.4 (3/6) 4.5±3.0 (3/6) 4.8±1.3 (3/6) 
Cyst S2 2.7±2.5 (10/10) nv (0/9*) nv (1/9*) nv (1/6) 4.6±4.1 (2/6) 5.4±3.2 (2/6) 
Cyst SA 2.7±4.5 (10/10) nv (0/9*) nv (1/9*) nv (1/6) nv (1) nv (1/6) 
Cyst SN 18±21 (10/10) nv (0/9*) 2.8±4.0 (4/9*) 4.7±6.4 (3/6) 5.3±1.4 (3/6) 5.4±3.0 (3/6) 
Levels expressed in Extracted Ion Current area  x 10^8 and detection frequency in brackets; pSS: primary Sjögren’s syndrome patients; sSS: 
secondary Sjögren’s syndrome patients; nv: not valuable;  *p<0.05 versus controls; °detection frequency significantly increased; †p<0.05 versus T0;  
‡ p<0.05 versus T0 and p>0.05 versus controls 
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Table 10. Histatins levels/frequency in controls, sSS and pSS before and after pilocarpine 
 
 
Controls(10)  sSS(9)   pSS(9) T0 pSS(6) T30’  pSS(6) T60’ pSS(6) T24 h 
Histastins       
Hist 1 11±26 (9/10) 4.6±7.5 (8/9) 1.1 ±2.0* (5/9) 1.6±1.6 (5/6) 2.2±2.5 (5/6) 4.0±8.3 (4/6) 
Hist 2 1.3±1.3 (9/10) 0.5±1.3 (3/9*) nv (1/9*) nv (1/6) 0.4±0.6 (3/6) 0.4±0.8 (2/6) 
Hist 3 4.1±5.7 (7/10) nv (1/9*) nv (1/9*) nv (1/6) 0.8±1.3 (2/6) 2.4±5.2 (2/6) 
Hist 4 0.3±0.3 (10/10) 0.7±2.0 (2/9*) nv (0/9*) nv (1/6) nv (0/6) nv (0/6) 
Hist 5 8.5±8.6 (9/10)  2.8±4.3 (7/9) 0.6±0.9 (4/9*) 0.7±1.1 (3/6) 1.5±1.7 (3/6) 2.6±4.3 (3/6) 
Hist 6 2.2±2.3 (9/10)  1.0±1.5 (5/9) 0.2±0.2 (4/9*) 0.3±0.4 (3/6) 0.3±0.5 (3/6) 0.7 ±1.6 (2/6) 
Hist 7 0.5±0.6 (10/10)  nv (1/9*) nv (0/9*) nv (1/6) nv (1/6) nv (0/6) 
Hist 8 0.4±0.2 (9/10) 0.3±0.5 (5/9) 0.1±0.1 (2/9*) 0.1±0.1 (3/6) 0.1±0.2 (3/6) 0.03±0.1 (1/6) 
Hist 9 0.1±0.2 (7/10) nv (0/9*) nv (0/9*) nv (0/6) nv (0/6) nv (0/6) 
Hist 11 0.08±0.1 (10/10) nv (0/9*) nv (0/9*) nv (0/6) nv (0/6) nv (0/6) 
Hist 12 0.1±0.1 (9/10) nv (0/9*) nv (0/9*) nv (0/6) nv (0/6) nv (0/6) 
Levels expressed in Extracted Ion Current area  x 10^8 and detection frequency in brackets; pSS: primary Sjögren’s syndrome patients; sSS: 
secondary Sjögren’s syndrome patients; nv: not valuable;  *p<0.05 versus controls; °detection frequency significantly increased; †p<0.05 versus T0;  
‡ p<0.05 versus T0 and p>0.05 versus controls 
 
 
 
 
 
 
 
Table 11. Immune peptides levels/frequency in controls, sSS and pSS before and after pilocarpine 
 
 
Controls(10)  sSS(9)   pSS(9) T0 pSS(6) T30’  pSS(6) T60’ pSS(6) T24 h 
Lysozime 0.5±0.3 (10/10) nv (1/9*) 0.3±0.6 (2/9*) 0.6±0.6 (4/6°) 0.6±0.7 (3/6) 0.3±0.4 (2/6) 
Defensins       
-1 1.6±1.5 (9/10) 6.0±9.0 (8/9) 13±14* (9/9) 11±12 (6/6) 13±12 (6/6) 10±12 (6/6) 
- 2 1.3±1.3 (8/10)  4.8±7.8 (8/9) 9.8±9.3 (9/9) 7.5±9.0 (6/6) 8.9±9.3 (6/6) 7.5±9.4 (6/6) 
- 3 0.7±0.9 (8/10) 4.6±9.1 (8/9) 8.5±9.4 (7/9) 5.6±9.8 (5/6) 6.1±9.3 (6/6) 6.0±11 (6/6) 
- 4 0.3±0.4 (9/10) 1.4±2.4 (7/9) 2.6±3.4 (6/9) 2.0±2.7 (4/6) 2.4±2.7 (4/6) 1.4±1.8 (4/6) 
- 1 nv (0/10) nv (0/9) nv (0/9) nv (0/6) nv (0/6) nv (0/6) 
- 2 nv (0/10) 0.1±0.4 (3/9) 1.9±4.6 (6/9*) 0.5±0.7 (3/6) 0.4±0.6 (2/6) 0.5±0.5 (3/6) 
-thymosins       
- 4 0.9±0.7 (8/10) 2.9±4.8 (7/9) 3.0±2.7 (8/9) 2.0±1.7 (5/6) 4.2±5.2 (5/6) 2.1±2.0  (5/6) 
- 10 nv (0/10) 0.2±0.3 (3/9*) 0.1±0.1 (6/9*) 0.7±0.1 (2/6*) 0.1±0.3  (2/6*) 0.2±0.2  (4/6*) 
Levels expressed in Extracted Ion Current area  x 10^8 and detection frequency in brackets; pSS: primary Sjögren’s syndrome patients; sSS: 
secondary Sjögren’s syndrome patients; nv: not valuable;  *p<0.05 versus controls; °detection frequency significantly increased; †p<0.05 versus T0;  
‡ p<0.05 versus T0 and p>0.05 versus controls 
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Protein profile after pilocarpine assumption 
In the 6 pSS patients who took 5 mg of pilocarpine, 5 proteins after 30 minutes after pilocarpine, 6 
after 60 minutes showed a significant increase in detection frequency in pSS patients than in basal 
specimen; 3 proteins were detectable even after 24 hours from pilocarpine (Tables 6-11 and figure 
2).  
After 30 and 60 minutes from pilocarpine assumption, the levels of 8 proteins increased 
significantly compared to basal specimens (Tables 6-11); 7 of these proteins were significantly less 
abundant at baseline than in controls and reached levels comparable to controls: IB-1, II-2, PRP-1 
PC and P-B peptide at 30 minutes and PRP-3 and statherin at 60 minutes after treatment with 
pilocarpine (Tables 6-11 and figure 2).  
Then, the secretion of 14 (21.9%) species among the proteins undetectable or with lower frequency 
of detection in basal pSS saliva seems to be stimulated by pilocarpine. Moreover pilocarpine 
showed to be able to restore levels similar to normal of the proteins with lower levels at basal 
specimens. 
The salivary cystatins proteins were the class of proteins less modified by pilocarpine. In fact the 
number of patients in which cystatins were detectable was similar before and after the drug 
somministration (Table 9). Basic and acidic PRPs and statherin group showed the best response to 
pilocarpine (Tables 6 and 7).  
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Figure 2 
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Analysis of the frequency and levels of salivary gland proteins in sSS patients vs pSS patients 
and healthy controls 
No significant differences between pSS and sSS patients in protein detection frequency were 
observed, with the exception of IB-6 which was more frequently detected in sSS patients (Table 6). 
IB-6 was present in 5/9 (55.6 %) sSS patients and in none of pSS patients. In particular IB-6 was 
detectable in all sSS patients with RA and in 2 sSS patients with SLE but in none of the sSS 
patients with SSc. P-B Des1-4, which was found in 6/9 (66.7 %) pSS patients, resulted detectable in 
3/9 (33.3 %) sSS patients (p=ns) (Table 8).  
Only two proteins (PRP-3 mono-Phos, PRP-3) resulted significantly less abundant in pSS than in 
sSS (Table 7).  
In sSS patients 20 (31.3 %) proteins showed a lower detection frequency than in controls (Tables 6-
11). IB-6 was significantly more represented in sSS patients (5/9) than in controls (1/10). As in pSS 
patients, the salivary cystatins were less frequently found in sSS patients than in controls. Instead 
the acidic PRPs showed a similar frequency in sSS patients than in controls. Only 2 proteins (4.5 % 
of proteins), statherin and IB-1, resulted significantly less abundant in sSS than in controls (Tables 
6 and 8). 
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Defensins  
No differences were found in -defensins 1-4 detection frequency between pSS, sSS patients and 
controls (Table 11). However -defensin-1 amounts was significantly higher in pSS patients than in 
controls (Table 11). The sSS patients had an intermediate -defensin-1 amount between pSS 
patients and controls. After pilocarpine assumption -defensin-1 levels became similar to controls at 
30, 60 minutes and 24 hours (Table 11). 
-defensin-1 was not detectable in patients and in controls. -defensin-2 was found in 6/9 (66.7 %) 
of pSS patients, in 3/9 (33.3 %) of sSS patients (2 SSc and 1 SLE) and in none of the controls 
(Table 11)). The 6 patients having -defensin-2 detectable, had increased -defensin-1 levels than 
the 3 patients without  -defensin-2 detectable (data not shown, p=ns). 
Thymosins 
TB4 was found in 8 (88.9%) of the patients with pSS, in 7 (77.8%) of the patients with sSS and in 8 
(80%) of the normal subjects (Table 11). 
TB10 was found in 6 (66.7%) of the patients with pSS, in 3 (33.3%) of the patients with sSS and in 
none of the normal subjects (Table 11). 
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DISCUSSION 
Recent studies suggest that xerostomia and xerophtalmia in pSS are due to functional inhibition of 
autonomic neurotransmission to lacrimal and salivary glands, rather than to infiltration and 
destruction of the glands by lymphocytes, because there is a poor correlation between degree of 
glandular destruction or focus score and degree of dysfunction (6, 68). A reduction in acetylcholine 
sensitivity in acinar cells from pSS patients (69) with a consequent up-regulation of M3R (68), the 
most important cholinergic receptors on salivary gland cells, has been reported. Moreover anti-
muscarinic receptor antibodies have been demonstrated in the serum of patients with pSS. These 
autoantibodies can inhibit parasympathetic neurotransmission (70) and the trafficking to the apical 
membrane of aquaporin 5, a water-channel protein which levels are increased by pilocarpine (71). 
Thus the study of pilocarpine effect on salivary gland function could be interesting for the 
comprehension of the pathogenesis of xerostomia in pSS patients. In fact, since pilocarpine has 
shown to increase salivary gland fluid secretion, our study found that pilocarpine can also increase 
the amount and the number of salivary proteins detectable in pSS patients.  
More than 50 % of salivary gland proteins analyzed in pSS patients were not detectable or showed 
lower levels than in healthy controls. About 20% of the proteins less represented in pSS patients 
reached a frequency similar to controls after 60 minutes from pilocarpine and 3 of these proteins 
were found in patients saliva even 24 hours later. All but one of the proteins with lower levels than 
in healthy controls before pilocarpine reached levels comparable to controls, most of them after 30-
60 minutes.  
These data suggest that pilocarpine could partially overcome the dysfunction in salivary glands 
affected by SS. Further studies will be necessary in order to confirm this hypothesis and to study the 
effects of chronic pilocarpine treatment. In fact a recent study showed that the chronic stimulation 
of membrane-bound M3R by circulating anti-M3R autoantibodies or pilocarpine esposition can 
result in receptor desensitization (72,73).   
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The salivary cystatins group (cystatin S, S1, S2, SN) showed to be the less represented class in pSS 
and sSS patients and showed the worst response to pilocarpine. While cystatin A showed a 
detection frequency similar to normal subjects, according to its not glandular origin, cystatin C, 
which levels were found increased in pSS patients parotid saliva in a recent SELDI-TOF-MS based 
study (6), was not detectable in any pSS or sSS patients. Since salivary cystatins had a principal 
submandibular/sublingual origin, these data suggest that submandibular and sublingual glands may 
be less susceptible to pilocarpine effect. Statherin fragments and the most part of acidic and basic 
PRPs, which showed a lower detection frequency in pSS patients, reached a similar frequency with 
respect to controls after 60 minutes from pilocarpine treatment. Statherin and all the other species 
less abundant at basal specimens reached levels not significantly different than healthy controls 
after pilocarpine somministration.  
The basic PRPs are of parotid origin while the acidic PRPs and statherin come from parotid, 
submandibular and sublingual glands. These data, together with the insufficient response to 
pilocarpine of the cystatins class, might suggest that parotid glands are the most sensitive to 
pilocarpine.  
P-B des1-4 and IB-6 seem to characterize pSS and sSS patients, respectively. However, larger 
studies should confirm these data. sSS patients showed a saliva proteins profile intermediate 
between pSS patients and controls. In fact the salivary cystatins were less frequently found in sSS 
patients as in pSS patients while the acidic PRPs were similar to controls in frequency. 
Although acidic PRPs and statherin role has not been completely understood, it seems related to 
oral calcium metabolism and to oral bacterial flora. Basic PRPs, together with acidic PRPs and 
statherin, seem to be involved in the formation of the protein net interacting with buccal epithelium 
and with dental enamel. Indeed the higher incidence of caries and parodontal diseases in pSS 
patients could be due to the reduction in those protein classes and may benefit from therapies which 
can restore a normal protein profile as pilocarpine has partially shown to do.  
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On the other hand our study showed higher amount of the imunopeptide defensins, which are not of 
glandular origin. Our study shows for the first time the presence of -defensins 1-4 in pSS and sSS 
patients saliva with significantly higher -defensin-1 amount in pSS patients. The increased amount 
of  -defensin-1 in pSS patients with respect to healthy subjects could be the result of the 
periodontal diseases which are common in pSS patients, thus suggesting a possible role of -
defensin-1 as a marker of oral inflammation in pSS patients. The reduction in -defensins amount 
after pilocarpine is likely due to the increased fluid secretion with consequent dilution and relative 
reduction in defensins concentration.      
Moreover our study demonstrates that -defensin-2 is detectable in the majority (66.7 %) of pSS 
patients and in none of the healthy subjects thus suggesting that -defensin-2 can be considered an 
inflammatory marker in pSS patients maybe reflecting high levels of cytokines such as IL 1, IL 6 
and TNF (74,75). Moreover this data is supported by the fact that pSS patients which had -
defensin-2 detectable tended to have increased -defensin-1 amounts. sSS patients had  -defensin-
1 levels intermediate between pSS and controls and only in 33.3 % of cases had  -defensin-2 
detectable maybe because the oral involvement is milder in sSS than in pSS patients.  
T-4, a G-actin sequestering peptide with anti-inflammatory and repairing properties, has been 
found detectable in all the patients and normal subjects, while T-10 has been found to be 
detectable in the majority of pSS patients, in 1/3 of sSS patients and in none of the healthy subjects.   
In conclusion pSS patients are characterized by a different frequency and different amounts of 
salivary gland proteins compared to healthy subjects. Pilocarpine showed to restore the amounts and 
partially the number of the proteins decreased in pSS patients with the parotid gland proteins having 
the best response to the drug assumption. High -defensin-1 amounts and the presence of -
defensin-2 and T-10 in pSS whole saliva could be markers of inflammation in Sjögren’s 
syndrome. Moreover sSS patients showed an intermediate protein profile between pSS and healthy 
subjects. All these data should be of help when considering the possible analysis of secretagogue 
function and the composition of salivary substitutes.
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